24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Anchiano
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:34
Unicorns Wonderful and Eon replace Meta at Tel Aviv's Sarona Tower
13:45
ServiceNow invests in Israeli cyber startup Clover Security
13:14
AI safety under fire as chatbots provide violent guidance
12:48
Nice CEO earns $12.8 million as shares slide 43%
More stories
Buzz
Most popular
Daily
Weekly
1
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
2
Former Mossad chief and real estate tycoons back controversial Israeli drone company
3
ServiceNow invests in Israeli cyber startup Clover Security
4
Jensen Huang: Nvidia “100% in Israel” despite war
5
Israel’s war with Iran costs up to $550 million a day
More news
Anchiano
2 stories about Anchiano
Anchiano Therapeutics Schedules TASE Delisting
14.03.19
|
Lilach Baumer
Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
09.01.19
|
Lilach Baumer
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter
